Korean J Fam Med.  2015 Sep;36(5):197-202. 10.4082/kjfm.2015.36.5.197.

An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians

Affiliations
  • 1College of Medicine, University of Nebraska Medical Center, Omaha, USA.
  • 2Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California (USC)/Norris Cancer Center, USC University Hospital, Los Angeles, USA. mojtaba.akhtari@med.usc.edu
  • 3Department of Pathology, Veterans Affairs West Los Angeles Medical Center, Los Angeles, USA.
  • 4Consultant Adult Hematology/BMT, Princess Noorah Oncology Center, Jeddah, Kingdom of Saudi Arabia.
  • 5Division of General Internal Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, USA.

Abstract

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. Forty percent of patients with CML are asymptomatic, in whom the disease is detected solely based on laboratory abnormalities. Since the introduction of tyrosine kinase inhibitor therapy in 2001, CML has become a chronic disease for the majority of patients. Primary care physicians may be the first to recognize a new diagnosis of CML. In patients with known CML, the primary care physician may be the first to detect disease progression or adverse effects to therapy. This article provides an overview of the clinical presentation, diagnostic approach, and treatment considerations of CML.

Keyword

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Primary Health Care

MeSH Terms

Adult
Chronic Disease
Diagnosis
Disease Progression
Humans
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Physicians, Primary Care*
Primary Health Care*
Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Full Text Links
  • KJFM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr